X
Pharma Advancement
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development

    Nasal Spray Shows Its Effect Against New COVID Variants

    Mid-Point Regulatory Science Strategy Study Published By EMA

    AADC Inadequacy To Be Handled By A Novel Gene Therapy

    New Drug Explored For Epilepsy Gets $3M Funding In Australia

    Care Access Research Launches Alliance to Provide Infrastructure for COVID-19 Trials

    Faster Clinical Trial Nods Planned By The UK To Curb Issues

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    U.S. FDA Approves DARZALEX Split-Dosing Regimen

    EMA Keeping A Close Watch On Critical Medicine Shortages

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Efficacy Shown On Cystic Fibrosis Patients In 4-Year Study

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development

    Nasal Spray Shows Its Effect Against New COVID Variants

    Mid-Point Regulatory Science Strategy Study Published By EMA

    AADC Inadequacy To Be Handled By A Novel Gene Therapy

    New Drug Explored For Epilepsy Gets $3M Funding In Australia

    Care Access Research Launches Alliance to Provide Infrastructure for COVID-19 Trials

    Faster Clinical Trial Nods Planned By The UK To Curb Issues

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    U.S. FDA Approves DARZALEX Split-Dosing Regimen

    EMA Keeping A Close Watch On Critical Medicine Shortages

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Efficacy Shown On Cystic Fibrosis Patients In 4-Year Study

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Drug Development Research & Development

NeuroVive’s genetic mitochondrial disease program NVP015 reaches significant milestone

Yuvraj_pawp by Yuvraj_pawp
1st December 2017
in Research & Development

NeuroVive Pharmaceutical AB, the mitochondrial medicine company, announced that molecules in its NVP015 program have demonstrated positive effects in experimental models of genetic mitochondrial disease and that a lead compound has been selected. The lead was selected based on tolerability, plasma stability and organ delivery, specifically to the brain, and will now be taken into further in vivo experimental efficacy studies and preclinical development.

The objective of NeuroVive’s NVP015 program is to develop a treatment option for patients with genetic mitochondrial diseases, such as Leigh Syndrome and MELAS, when acute cellular energy support is needed, such as during an ordinary infection. These patients are at risk of further deterioration in their disease and symptoms during such energy crisis.

“We are very pleased with the progress in the NVP015 program which, together with our KL1333 program, shows our strong commitment to the development of novel treatments for genetic mitochondrial diseases,” commented Magnus Hansson, M.D., Ph.D., chief medical officer and VP of Preclinical and Clinical Development at NeuroVive.

NeuroVive collaborates with Dr. Marni Falk’s research lab at the Children’s Hospital of Philadelphia (CHOP) to evaluate the NVP015 compound class. Top line data from these studies demonstrates that the compounds exert beneficial effects in experimental C. elegans models of genetic mitochondrial disease. Approximately 50 per cent of genetic mitochondrial disease patients have a complex I dysfunction (isolated or in combination with other defects) in the mitochondria. Complex I dysfunction occurs when the first of the five complexes in the mitochondrial respiratory chain fails to function normally, resulting in the mitochondria being unable to generate enough cellular energy, ATP.

“This is a breakthrough which takes us a step closer to our goal of developing a therapy for acute energy crisis situations in genetic mitochondrial disease patients. Currently, patients with these types of genetic mitochondrial disorders can only be offered symptomatic treatment alternatives, whereas the aim of the NVP015 program is to create a drug that can bypass the dysfunction, helping the mitochondria to function properly,” said Eskil Elmér, M.D., Ph.D., chief scientific officer and VP of Discovery at NeuroVive.

Previous Post

UCB showcases new research and continued epilepsy leadership at the 2017 American Epilepsy Society Annual Meeting

Next Post

Cancer Genetics and ICON to reduce cancer mortality rate in India

Related Posts

Tumors Can Get Destroyed By Bacteria-Aid To Immune System
News

Tumors Can Get Destroyed By Bacteria-Aid To Immune System

16th March 2023
News

Researchers Develop Revolutionary Treatment In Bone Cancer

10th March 2023
News

T Cells Are Fruitful In Thwarting-Off Chronic Infections

10th March 2023
News

Randomness Drives Tumour Cells Response To Chemotherapy

10th March 2023
Featured

Animal Testing Could See An End With An Artificial Model

28th February 2023
Featured

Germany Rolls First CAR-T Push For Muscle Inflammation Cure

27th February 2023
Next Post

Cancer Genetics and ICON to reduce cancer mortality rate in India

Latest News

Cathay Cargo signs global airline partnership with Tower Cold Chain
Packaging & Logistic

Cathay Cargo signs global airline partnership with Tower Cold Chain

31st March 2023
Quotient Sciences completes integration of drug substance into Translational Pharmaceutics Platform
Facilities & Operation

£277m Funding Set To Benefit UK Life Sciences Manufacturing

31st March 2023
Drug Development

Nasal Spray Shows Its Effect Against New COVID Variants

27th March 2023
FDA Approvals

Mid-Point Regulatory Science Strategy Study Published By EMA

27th March 2023
Drug Development

AADC Inadequacy To Be Handled By A Novel Gene Therapy

24th March 2023
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack

System

  • Search
  • Sitemap
  • RSS Feed

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In